PLX Protalix BioTherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1006281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.0%
TTM net income YoY281.0%
TTM EPS YoY200.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR24.6%
Margins
Gross margin71.2%
Operating margin29.8%
Net margin24.3%
FCF margin17.8%
EBITDA margin31.7%
Returns
ROE30.8%
ROA20.5%
ROIC (approx.)41.0%
Asset turnover0.84x
Leverage & solvency
Liabilities / assets31.9%
Debt / equity0.00x
Current ratio3.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio3.0%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $52.74M | $53.40M | $65.49M | $47.64M | $38.35M |
| Cost of revenue | $26.99M | $24.32M | $22.98M | $19.59M | $16.35M |
| Gross profit | $25.75M | $29.08M | $42.51M | $28.05M | $22.00M |
| R&D expense | $19.57M | $12.97M | $17.09M | $29.35M | $29.73M |
| SG&A expense | $11.68M | $12.19M | $14.96M | $11.71M | $12.73M |
| Operating income | -$5.50M | $3.92M | $10.46M | -$13.01M | -$20.46M |
| Pretax income | -$5.61M | $4.15M | $8.57M | -$14.40M | -$27.58M |
| Income tax | $996,000 | $1.22M | $254,000 | $530,000 | — |
| Net income | -$6.60M | $2.93M | $8.31M | -$14.93M | -$27.58M |
| EBITDA | -$4.04M | $5.22M | $11.65M | -$11.93M | -$19.34M |
| EPS (basic) | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 |
| EPS (diluted) | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 |
| Weighted avg. shares (diluted) | 78.55M | 81.06M | 82.42M | 48.47M | 44.14M |
| Balance sheet | |||||
| Cash & equivalents | $14.68M | $19.76M | $23.63M | $17.11M | $38.98M |
| Receivables | $8.84M | $2.91M | $5.27M | $4.59M | $3.44M |
| Inventory | $25.73M | $21.24M | $19.05M | $16.80M | $17.95M |
| Current assets | $66.67M | $60.08M | $69.93M | $44.88M | $61.67M |
| PP&E, net | $4.88M | $4.59M | $4.97M | $4.55M | $4.96M |
| Total assets | $82.35M | $73.42M | $84.43M | $55.79M | $73.67M |
| Current liabilities | $26.52M | $25.62M | $45.53M | $32.43M | $33.18M |
| Total liabilities | $34.12M | $30.21M | $50.87M | $66.43M | $79.70M |
| Shareholders' equity | $48.23M | $43.21M | $33.57M | -$10.64M | -$6.04M |
| Shares outstanding | 80.43M | 75.85M | 72.95M | 53.79M | 45.56M |
| Cash flow statement | |||||
| Operating cash flow | -$11.99M | $8.67M | -$1.32M | -$25.00M | -$10.29M |
| Capital expenditure | $1.64M | $1.28M | $1.15M | $628,000 | $1.46M |
| Free cash flow | -$13.63M | $7.39M | -$2.47M | -$25.63M | -$11.74M |
| Investing cash flow | -$2.37M | $4.22M | -$16.71M | -$5.04M | $18.92M |
| Financing cash flow | $9.33M | -$16.79M | $24.67M | $8.24M | $12.08M |
| Depreciation & amortization | $1.47M | $1.30M | $1.19M | $1.09M | $1.12M |
| Stock-based compensation | $2.30M | $3.25M | $3.45M | $2.08M | $2.38M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.